Importantly, high levels of plasma MEG3 were linked with longer survival in BRAFi‐treated CM patients, whereas CYLD downregulation might protect CM cells from BRAFi/MEKi‐induced apoptosis. The gene discussed is MEG3; the disease is cutaneous mastocytosis.